Using the Shanghai Municipal Health Commission database and Shanghai Centers for Disease Control and Prevention database, patients with AF in Shanghai are included to construct the Shanghai AF registry to investigate clinical characteristics, treatment, and prognosis.
1. To determine the most suitable risk stratification model for Chinese AF population regarding stroke and major cardiovascular events, i.e. CHA2DS2-VASc, CHA2DS2-VASc-60, or CHA2DS2-VA scores. 2. To compare the clinical prognosis of patients with AF receiving the combined procedure of catheter ablation and left atrial appendage closure (LAAC), single catheter ablation, and single LAAC.
Study Type
OBSERVATIONAL
Enrollment
400,000
Compare the clinical prognosis of patients with AF underwent the combined procedure of catheter ablation and left atrial appendage closure (LAAC), single catheter ablation and single LAAC.
Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China
Composite of death, ischemic stroke, systemic embolism, myocardial infarction, major bleeding, and acute heart failure
Composite of death, ischemic stroke, systemic embolism, myocardial infarction, major bleeding, and acute heart failure
Time frame: From enrollment to December 31, 2024
Cardiovascular death
Death due to the following reasons: Ischemic heart diseases; Hypertensive heart diseases; Other heart and vascular diseases, including myocarditis, endocarditis, pulmonary embolism, aortic aneurysm, dissecting aneurysm; Sudden, unexpected, and unwitnessed death or death of unknown cause; Ischemic stroke; Hemorrhagic stroke and non-traumatic intracranial bleeding
Time frame: From enrollment to December 31, 2024
Non-cardiovascular death
Death caused by: Alzheimer's disease, Parkinson's disease, other neurological diseases except vascular central nervous system causes; Diabetes mellitus; Cancers (malignant solid tumors); Chronic obstructive pulmonary disease, lower respiratory infections, and other respiratory diseases; Gastrointestinal and liver diseases; Chronic kidney diseases and other kidney diseases; Leukemia, lymphoma, and other diseases of blood system; Falls; Road injuries; Drowning and asphyxia; Self-harm; COVID-19; Other non-cardiovascular causes of death, etc.
Time frame: From enrollment to December 31, 2024
Ischemic stroke
* Neurological deficit of cerebrovascular cause that persists beyond 24 hours or is interrupted by death within 24 hours. * Exclusion of coma due to severe brain trauma, intracranial tumor, metabolic disorder or fluid or electrolyte imbalance, peripheral neuropathy, or CNS infection. * Not meeting criteria for subarachnoid hemorrhage, intraparenchymal hemorrhage and other hemorrhage * With imaging findings
Time frame: From enrollment to December 31, 2024
Systemic embolism
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
* Acute vascular insufficiency or occlusion of the extremities or any non-CNS organ associated with clinical, imaging, surgical/autopsy evidence of arterial occlusion. * Exclusion of other likely mechanism, e.g., trauma, atherosclerosis, or instrumentation, etc.
Time frame: From enrollment to December 31, 2024
Myocardial infarction
* A rise of cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit and with at least one of the following: * Symptoms of ischemia * ECG evidence: new ST-segment-T wave (ST-T) changes, or new left bundle branch block, or new pathological Q waves * Imaging evidence: new loss of viable myocardium or new regional wall motion abnormality * Angiography evidence: intracoronary thrombus
Time frame: From enrollment to December 31, 2024
Major bleeding
At least one of the following conditions: * Fatal bleeding * Symptomatic bleeding in a critical organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome * Bleeding causing a fall in hemoglobin level of 20 g/L or more or leading to transfusion of two or more units of whole blood or red cells.
Time frame: From enrollment to December 31, 2024
Acute Heart failure (HF)
* Hospitalization, or emergency department visit requiring treatment with infusion therapy, for a clinical syndrome that presents with multiple signs and symptoms consistent with cardiac decompensation or inadequate cardiac pump function. * Evidence in the doctor's notes that the reason for this hospitalization, or emergency department visit, was heart failure. * Evidence of signs and symptoms: increasing or new onset shortness of breath, edema, paroxysmal nocturnal dyspnea, orthopnea, and hypoxia * Include acute decompensated HF with preserved, mid-range, and reduced left ventricular ejection fraction. * If a patient was diagnosed and treated for HF in an outpatient setting without infusion therapy for decompensated HF, such condition was not considered an outcome.
Time frame: From enrollment to December 31, 2024